Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Adv Emerg Nurs J ; 38(4): 279-294, 2016.
Article in English | MEDLINE | ID: mdl-27792070

ABSTRACT

It is not uncommon for providers in the emergency department to take care of patients who are taking anticoagulant therapy in the outpatient setting. However, the bigger challenge is caring for these patients when they present with bleeding that could be secondary to 1 or more of these medications. In recent years, this class of medications has expanded from warfarin to include direct thrombin inhibitors and Factor Xa inhibitors. As this class of medications has evolved, so has the approach to the reversal of these agents. Thus, it is imperative that providers in the emergency department be familiar not only with the anticoagulants that patients may be taking in the outpatient setting but also with their reversal agents.


Subject(s)
Anticoagulants/adverse effects , Antidotes/therapeutic use , Emergency Service, Hospital , Hemorrhage/etiology , Hemorrhage/prevention & control , Humans
2.
Adv Emerg Nurs J ; 38(2): 93-108, 2016.
Article in English | MEDLINE | ID: mdl-27139131

ABSTRACT

Hereditary angioedema attacks are rare, but emergency care providers must be aware of the clinical presentation and treatment of these patients because the emergency department remains the most common setting where these patients seek treatment. If providers are not aware of the past medical history of these patients, they are likely to receive standard therapies for respiratory distress and anaphylaxis including antihistamines, corticosteroids, and epinephrine. However, these medications may not work in these patients, given the pathophysiology of their underlying disease. Since 2009, several new therapies have been approved for the treatment of acute hereditary angioedema attacks. This article discusses pathophysiology, clinical presentation, and use of novel therapies for the management of angioedema.


Subject(s)
Angioedemas, Hereditary/drug therapy , Complement C1 Inactivator Proteins/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Angioedemas, Hereditary/diagnosis , Angioedemas, Hereditary/physiopathology , Emergency Service, Hospital , Epinephrine/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Plasma
SELECTION OF CITATIONS
SEARCH DETAIL
...